The company, headquartered in Englewood Cliffs, New Jersey, with a subsidiary company in Munich Germany, focuses on developing novel and effective prescription pain products that use a topical delivery approach. This approach delivers drugs to a target area, as opposed to systemic or transdermal modes, and is protected by an aggressive patent program. EpiCept aims to partner with third-party collaborators for co-marketing, co-promotion, licensing, and distribution arrangements. The company's products have significant market potential and are also intended for the treatment of cancer.